Expanding Expanded Access: The Long-Term Implications of the Abigail Alliance Lawsuit
This article was originally published in RPM Report
Executive Summary
A patient advocate's lawsuit against FDA has provided plenty of fodder for debates on the constitutional right of patients to try unapproved drugs. If the case is upheld on appeal, there will be serious long-term consequences for both drug sponsors and managed care.